|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 9/00 | |
| A61K 9/16 | |||
| A61K 31/712 | |||
| C07K 16/22 | |||
| A61P 27/02 |
| (11) | Patento numeris | 2664347 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 13179231.9 |
| Europos patento paraiškos padavimo data | 2009-07-13 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-11-20 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-03-13 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 176238 | 2008-07-18 | US |
| (72) |
Robinson, Michael R., US
Blanda, Wendy M., US
Hughes, Patrick M., US
Burke, A. James, US
Whitcup, Scott M., US
|
| (73) |
ALLERGAN, INC.,
2525 Dupont Drive, Irvine, CA 92612,
US
|
| (54) | Bevacizumab for use in a method for treating atrophic age related macular degeneration |
| Bevacizumab for use in a method for treating atrophic age related macular degeneration |